Skip to content

Medical Abortion With Mifepristone + Misoprostol (13 - 22 Weeks)

Medical Abortion With Mifepristone + Misoprostol (13 - 22 Weeks): A Double-blind Randomized-controlled Trial

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01768299
Enrollment
504
Registered
2013-01-15
Start date
2013-02-28
Completion date
2014-05-31
Last updated
2014-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complete Uterine Evacuation After Use of Study Drugs

Keywords

abortion, medical abortion, mifepristone, misoprostol

Brief summary

A double-blind randomized controlled trial to compare a shorter interval between the administration of mifepristone and misoprostol (simultaneous administration compared to 24hours from administration of mifepristone to receipt of the first dose of misoprostol) for termination of pregnancy up to 13-22 weeks of gestation. The investigators hypothesize that a shortened interval may achieve comparable efficacy in terminating pregnancy, whilst reducing the duration of the procedure and in turn, the duration of hospitalization.

Interventions

DRUGMifepristone

200 mg oral Mifepristone 24 hours before 400 mcg buccal misoprostol

DRUGMisoprostol

200 mg oral Mifepristone simultaneously 400 mcg buccal misoprostol

Sponsors

Gynuity Health Projects
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
Yes

Inclusion criteria

* Closed cervical os and no vaginal bleeding * Live fetus at time of presentation for service * No contraindications to medical abortion and study procedures, according to provider * Able to consent to participate in the study, either by reading consent document or by having consent document read to her and sign informed consent * Willing to follow study procedures

Exclusion criteria

* Known previous transmural uterine incision * \> 5 parity * Signs and symptoms of infection * Any contraindications to vaginal delivery, including placenta previa * Presentation in active labor (defined as moderate to severe contractions every 10 minutes or less)

Design outcomes

Primary

MeasureTime frameDescription
Proportion of women who have had a complete uterine evacuation within 24 hours using study drug without recourse to any additional intervention.Within 1 weekDefined as complete evacuation of fetus and placenta using study drug without recourse to any additional intervention.

Secondary

MeasureTime frameDescription
Rate of fetal expulsionWithin 1 weekDefined as fetal expulsion with study drug alone.
Induction to abortion intervalWithin 1 weekDefined as time elapsed between administration of the first misoprostol dose until expulsion of the fetus and placenta.
Women's acceptability of the assigned method.Within 1 week
Time interval from the mifepristone dose to abortionWithin 1 weekDefined as length of time from initiation of mifepristone to complete abortion achieved.
Total dose of misoprostol administeredWithin 1 week
Provision of additional interventionsWithin 1 weekFor example: Uterine massage, Manual removal, Sponge forceps, D&C or D&E, Repeat medical abortion drugs

Countries

Vietnam

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026